Boehringer's Spiriva: Advancing COPD Therapy

Boehringer Ingelheim's new COPD treatment, Spiriva, could be a blockbuster--particularly if its worldwide marketing partner Pfizer can increase diagnosis of the disease and expand COPD drugs' prescribing base from specialists to GPs. But, complicating matters for Boehringer, Pfizer--through its proposed acquisition of Pharmacia--will also market the PDE-4 inhibitor roflumilast, Altana's next-generation COPD therapy.

The second-generation anticholinergic bronchodilator tiotropium (Spiriva) has drawn its share of attention. The once-a-day treatment for chronic obstructive pulmonary disease (COPD) from Boehringer Ingelheim GMBH has been hailed as this year's most important new Big Pharma drug, with some analyst predicting peak sales in excess of $2 billion. They've been encouraged by Spiriva's European roll-out, which began in June: the drug is now available on more than a dozen markets worldwide. An FDA decision is expected at any moment—following a unanimous advisory committee recommendation.

Spiriva's success was expected. Until Pfizer Inc. finally won the competition, signing a worldwide marketing partnership for the drug,...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo